GenSight Biologics S.A. (0RIM.L)
| Previous close | 2.2200 |
| Open | 2.2180 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2000 - 2.3860 |
| 52-week range | 2.2000 - 2.3860 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 677,119 |
| Beta (5Y monthly) | 2.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6330 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
GenSight Biologics Reports Full Year 2022 Consolidated Financial Results
PARIS, March 24, 2023--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its full year 2022 consolidated financial results, as approved by the Board of Directors on March 23, 2023. Audit procedures on the Company’s 2022 consolidated financial statements were comp
- Business Wire
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
PARIS, March 15, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314006021/en/
- Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
PARIS, March 13, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230312005028/en/
